Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
Self et al., The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00751-9
https://c19early.org/self3.html